Belgium-based Imcyse Secures 35M Euros with Type 1 Diabetes Focus

DIABETES CONCEPT TrialsiteN

Belgium-based Imcyse has raised 35 million Euros Series B round to develop a potential cure for chronic autoimmune conditions including type 1 diabetes and multiple sclerosis.

Imcyse uses modified peptides that cause the destruction of rogue immune cells attacking healthy tissue in an autoimmune condition. Designed to halt autoimmune conditions long-term, with the hopes of a potential cure, the therapy targets specific cells and is designed to leave the rest of the immune system intact, reports Labiotech.

Standard of Care

Today most type 1 diabetes patients are primarily given insulin for the rest of their lives. New treatments harnessing the immune system to halt the destruction of insulin-producing cells might hold the key to beating the condition for good.

Series B Investors

Life Science Partners, Netherlands

Additionally, they received 4.6 million Euros from the public sector as well as a 2 million loan from the Belgian bank Belarus to advance treatments.

Clinical Activity

Imcyse presently has one study registered in ClinicalTrials.gov

Their clinical study has been evaluating the safety of an innovative approach expected to be disease-modifying by stopping the autoimmune-mediated destruction of islet β-cells in the pancreas. Three doses of the investigational product are being tested in successive cohorts. Although safety is the first objective of this study, they seek to gather efficacy data and perform a set of immunological tests to further understand the mechanism of action of this new approach in young adults with recent-onset type 1 diabetes.

They initially targeted 41 patients and it looks as if they have settled on 40.

Imcyse Research Sites

Imcyse is working with approximately 15 sites across Europe including the lead investigative site in France. Sites include:

  •         Hospital Erasme, Brussels Belgium
  •         Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
  •         CHU de Nantes, Hospital Laennec, Nantes, France
  •         GWT-TUD GmbH, Dresden, Germany
  •         Klaipeda University Hospital, Klaipeda, Lithuania
  •         University Hospital Santaros Klinikos, Vilnius, Lithuania
  •         Clinical Trial Center, CTC, Göteborg, Stockholm, Sweden
  •         ProbarE Stockholm, Stockholm, Sweden
  •         Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  •         Cardiff University, Cardiff UK
  •         Royal Devon and Exeter NHS Trust, Exeter, UK
  •         Guy’s and St. Thomas NHS Trust, London, UK
  •         St. Bartholomew’s Hospital (Barts Health NHS Trust)
  •         Oxford University Hospitals, NHS Foundation Trust
  •         Lead Research/Investigator
  •         Christian Boitard, MD Hospital Cochin, Paris, France